Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015:2015:785793.
doi: 10.1155/2015/785793. Epub 2015 Jan 20.

Evaluating the feasibility of performing window of opportunity trials in breast cancer

Angel Arnaout  1 , Susan Robertson  2 , Iryna Kuchuk  3 , Demetrios Simos  3 , Gregory R Pond  4 , Christina L Addison  5 , Mehrzad Namazi  6 , Mark Clemons  7
Affiliations
Clinical Trial

Evaluating the feasibility of performing window of opportunity trials in breast cancer

Angel Arnaout et al. Int J Surg Oncol. 2015.

Abstract

Background: The waiting period to surgery represents a valuable "window of opportunity" to evaluate novel therapeutic strategies. Interventional studies performed during this period require significant multidisciplinary collaboration to overcome logistical hurdles. We undertook a one-year prospective window of opportunity study to assess feasibility.

Methods: Eligible newly diagnosed postmenopausal, estrogen receptor positive breast cancer patients awaiting primary surgery received anastrozole daily until surgery. Feasibility was assessed by (a) the proportion of patients who consented and (b) completed the study. Comparison of pre- and poststudy Ki67 labelling index and cleaved caspase 3 scores (CC3) was performed.

Results: 22/131 (16.8%) patients were confirmed eligible and 20/22 (91%) patients completed the study. 19/20 (95%) patients agreed to undergo optional additional tissue biopsies. The mean duration of anastrozole use was 24.7 (15-44) days. There were a statistically significant decline in mean Ki67 indices of 48.8% (p < 0.001) and a trend towards significance in the decline of CC3 (p = 0.17) when comparing pre- with posttreatment values.

Conclusion: window of opportunity trials in breast cancer are a feasible way of assessing the biologic efficacy of different therapies in the presurgical setting. The majority of eligible women were willing to participate including undergoing additional tissue biopsies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study schema.
Figure 2
Figure 2
Patient flowchart.
Figure 3
Figure 3
Ki67 labelling index (a) and cleaved caspase 3 (CC3) (b) at baseline and after anastrozole treatment at surgery.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Henderson I. C. Window of opportunity. Journal of the National Cancer Institute. 1991;83(13):894–896. doi: 10.1093/jnci/83.13.894. - DOI - PubMed
    1. Kalinsky K., Hershman D. L. Cracking open window of opportunity trials. Journal of Clinical Oncology. 2012;30(21):2573–2575. doi: 10.1200/JCO.2012.42.3293. - DOI - PubMed
    1. Wisinski K. B., Faerber A., Wagner S., et al. Predictors of willingness to participate in window of opportunity breast trials. Clinical Medicine and Research. 2013;11(3):107–112. doi: 10.3121/cmr.2013.1136. - DOI - PMC - PubMed
    1. Glimelius B., Lahn M. Window of opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of Oncology. 2011;22(8):1717–1725. doi: 10.1093/annonc/mdq622. - DOI - PubMed
    1. Hilton J., Arnaout A., Clemons M. Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates. Current Opinion in Supportive and Palliative Care. 2014;8(1):53–58. doi: 10.1097/SPC.0000000000000026. - DOI - PubMed

Publication types

MeSH terms